73 related articles for article (PubMed ID: 23267208)
1. PD-1 regulates the growth of human mastocytosis cells.
Kataoka TR; Fujimoto M; Moriyoshi K; Koyanagi I; Ueshima C; Kono F; Tsuruyama T; Okayama Y; Ra C; Haga H
Allergol Int; 2013 Mar; 62(1):99-104. PubMed ID: 23267208
[TBL] [Abstract][Full Text] [Related]
2. SLAM family member 8 is involved in oncogenic KIT-mediated signalling in human mastocytosis.
Sugimoto A; Kataoka TR; Ueshima C; Takei Y; Kitamura K; Hirata M; Nomura T; Haga H
Exp Dermatol; 2018 Jun; 27(6):641-646. PubMed ID: 29498772
[TBL] [Abstract][Full Text] [Related]
3. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
4. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism.
Sugita S; Usui Y; Horie S; Futagami Y; Yamada Y; Ma J; Kezuka T; Hamada H; Usui T; Mochizuki M; Yamagami S
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):263-72. PubMed ID: 18775867
[TBL] [Abstract][Full Text] [Related]
5. Variability of PD-L1 expression in mastocytosis.
Hatch EW; Geeze MB; Martin C; Salama ME; Hartmann K; Eisenwort G; Blatt K; Valent P; Gotlib J; Lee JH; Chen L; Ward HH; Lidke DS; George TI
Blood Adv; 2018 Feb; 2(3):189-199. PubMed ID: 29378725
[TBL] [Abstract][Full Text] [Related]
6. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.
Wasag B; Niedoszytko M; Piskorz A; Lange M; Renke J; Jassem E; Biernat W; Debiec-Rychter M; Limon J
Exp Hematol; 2011 Aug; 39(8):859-65.e2. PubMed ID: 21689725
[TBL] [Abstract][Full Text] [Related]
7. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
8. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.
Sugita S; Usui Y; Horie S; Futagami Y; Aburatani H; Okazaki T; Honjo T; Takeuchi M; Mochizuki M
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2862-70. PubMed ID: 19182257
[TBL] [Abstract][Full Text] [Related]
9. Porcine PD-L1: cloning, characterization, and implications during xenotransplantation.
Jeon DH; Oh K; Oh BC; Nam DH; Kim CH; Park HB; Cho J; Lee JR; Lee DS; Lee G
Xenotransplantation; 2007 May; 14(3):236-42. PubMed ID: 17489864
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of costimulatory molecules in Behçet's disease according to clinical activity.
Sim JH; Park MJ; Park S; Lee ES
Br J Dermatol; 2011 Jun; 164(6):1285-91. PubMed ID: 21574973
[TBL] [Abstract][Full Text] [Related]
11. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1.
Lauden L; Boukouaci W; Borlado LR; López IP; Sepúlveda P; Tamouza R; Charron D; Al-Daccak R
Circ Res; 2013 Feb; 112(3):451-64. PubMed ID: 23243206
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.
Li W; Wang X; Chen R; Zhu H; Chen G; Sun X
J Surg Res; 2012 Aug; 176(2):e79-87. PubMed ID: 22381170
[TBL] [Abstract][Full Text] [Related]
13. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.
Fisicaro P; Valdatta C; Massari M; Loggi E; Ravanetti L; Urbani S; Giuberti T; Cavalli A; Vandelli C; Andreone P; Missale G; Ferrari C
Gastroenterology; 2012 Dec; 143(6):1576-1585.e4. PubMed ID: 22929808
[TBL] [Abstract][Full Text] [Related]
14. [Effect of methylation inhibitor on demethylation pattern of the PD-1 gene in promoter region and PD-1 expression in human T lymphocyte cell line].
Zhang M; Xiao X; Liang Y; Peng M; Jiang Y; Xu Y; Gong G
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Dec; 36(12):1163-9. PubMed ID: 22246361
[TBL] [Abstract][Full Text] [Related]
15. Human amnion mesenchymal cells negative co-stimulatory molecules PD-L1 expression and its capacity of modulating microglial activation of CNS.
Wu W; Lan Q; Lu H; Xu J; Zhu A; Fang W; Ge F; Hui G
Cell Biochem Biophys; 2014 May; 69(1):35-45. PubMed ID: 24096708
[TBL] [Abstract][Full Text] [Related]
16. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis.
Longley BJ; Morganroth GS; Tyrrell L; Ding TG; Anderson DM; Williams DE; Halaban R
N Engl J Med; 1993 May; 328(18):1302-7. PubMed ID: 7682288
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis.
Ding H; Wu X; Gao W
Clin Immunol; 2005 May; 115(2):184-91. PubMed ID: 15885642
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of cytolytic activity of human effector cells by transgenic expression of human PD-ligand-1 on porcine target cells.
Plege A; Borns K; Beer L; Baars W; Klempnauer J; Schwinzer R
Transpl Int; 2010 Dec; 23(12):1293-300. PubMed ID: 20579316
[TBL] [Abstract][Full Text] [Related]
19. [Gene copy number, mRNA transcription and protein expression of PD-1 gene in primary hepatocarcinoma patients].
Fan HM; Wu LJ; Hu FY; Yang Z
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Aug; 26(4):282-4. PubMed ID: 23189845
[TBL] [Abstract][Full Text] [Related]
20. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
